Results 151 to 160 of about 133,417 (336)

Induction chemotherapy with paclitaxel, carboplatin, and cetuximab (PCE) followed by chemoradiotherapy for unresectable locoregional recurrence after curative surgery in patients with squamous cell carcinoma of the head and neck

Frontiers in Oncology
BackgroundThe significance of induction chemotherapy (IC) in the treatment of squamous cell carcinoma of the head and neck (SCCHN) with unresectable locoregional recurrence after curative surgery has not been clarified.
Masanobu Sato, Masanobu Sato, Masanobu Sato, Tomohiro Enokida, Takao Fujisawa, Susumu Okano, Naohiro Takeshita, Naohiro Takeshita, Nobukazu Tanaka, Hideki Tanaka, Atsushi Motegi, Sadamoto Zenda, Takeshi Shinozaki, Kazuto Matsuura, Ryuichi Hayashi, Tetsuo Akimoto, Makoto Tahara   +16 more
doaj   +1 more source

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model [PDF]

, 2001
Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz, Tania Trippett, Eric Hedrick, Daniel A. Filippa, Diane C. Louie, Maria Gonzales, Janine Walits, Nancy Coady-Lyons, Jing Qin, Richard C. Frank, Joseph R. Bertino, André Goy, Ariela Noy, James P. O'Brien, David J. Straus, Carol S. Portlock, Joachim Yahalom   +18 more
openalex   +1 more source

Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination With Cobicistat

The Journal of Clinical Pharmacology, EarlyView.
Abstract Pharmacokinetic boosting can be a strategy to enhance osimertinib exposure and reduce treatment associated costs. The OSIBOOST trial demonstrated that it was feasible to boost low osimertinib plasma trough levels with cobicistat. The current study aims to establish the equivalent dose of cobicistat boosted osimertinib compared to osimertinib ...
Niels Westra, Paul D. Kruithof, Sander Croes, Robin M. J. M. van Geel, Lizza E. L. Hendriks, Daan J. Touw, Jos G. W. Kosterink, Jasper Stevens, Thijs H. Oude Munnink, Paola Mian   +9 more
wiley   +1 more source

Improving Chemoradiotherapy in Rectal Cancer [PDF]

, 2001
Rob Glynne‐Jones
openalex   +1 more source

Comprehensive Analysis of Chyle Leak in Resected Pancreatic Head Cancer: Impact on Clinical, Oncologic, and Nutritional Outcomes

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background Chyle leak (CL) is a relevant complication of pancreatic surgery, but its incidence, risk factors, clinical and oncologic impacts, and nutritional relevance remain inconsistent and limited. Methods We retrospectively reviewed patients who underwent pancreaticoduodenectomy for pancreatic head cancer from 2007 to 2023 at a single ...
Jae Seung Kwak, Chang Moo Kang, Ho Kyoung Hwang, Sung Hyun Kim, Seung Soo Hong   +4 more
wiley   +1 more source

Therapeutic Results of Alternating Chemoradiotherapy for Nasopharyngeal Cancer using Cisplatin and 5-Fluorouracil: Its Usefulness and Controversial Points [PDF]

, 2001
Nobukazu Fuwa
openalex   +1 more source

The Impact of Intraoperative Radiotherapy on Margin Positive Locally Advanced Rectal Cancer: A Propensity‐Matched Analysis of The National Cancer Database

Journal of Surgical Oncology, EarlyView.
ABSTRACT Purpose Intraoperative radiotherapy (IORT) is utilized as an adjunctive treatment in advanced rectal cancer, particularly in cases with threatened surgical margins. Although IORT has shown benefits in enhancing local tumor control, its impact on overall survival (OS) remains unclear.
Metincan Erkaya, Salih Karahan, Mustafa Oruc, Sudha R. Amarnath, Jacob A. Miller, Ali Alipouriani, Brogan Catalano, Scott Steele, Emre Gorgun   +8 more
wiley   +1 more source

Life threatening laryngeal toxicity following treatment with combined chemoradiotherapy for nasopharyngeal cancer: A case report with review of the literature

, 1999
Sally Baron‐Hay, Anthony Clifford, Michael Jackson, Sharon E. Clarke   +3 more
openalex   +1 more source

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregional Esophageal Cancer [PDF]

, 2001
Gyeong Won Lee, Jung Hun Kang, Hun Gu Kim, In Gyu Hwang, Ki Shik Shim, Seok Hyun Kim, Won Sep Lee, Woon Tae Jung, Ok‐Jae Lee, Jung Hyeun Cho, Joung Soon Jang, Kyu Young Chae, Jong Seok Lee   +12 more
openalex   +1 more source

Rhaponitin Reverses Cisplatin Resistance and Impairs Cancer Stemness Through HIF‐1α/MCT4/Wnt Pathway in Tongue Squamous Cell Carcinoma

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Rhaponitin (Rha) possesses anti‐tumor activity and mediates the transcriptional activity of hypoxia‐inducible factor (HIF)‐1α that affects cisplatin (Cis) resistance. However, whether Rha can lessen Cis resistance in tongue squamous cell carcinoma (TSCC) by mediating HIF‐1α activity is unclear. Cis‐resistant SCC9 (SCC9‐CisR) cells were treated
Yuan Wu, Xiao‐Wen Wan, Lin Jiang, Wei Wang, Jia‐Jun Zhu, Yi‐Sen Shao   +5 more
wiley   +1 more source